Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring hospitalization. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease and cancer are more likely to develop serious illness.
At this time, there are no specific vaccines or treatments for COVID-19. However, more than 250 potential treatments are being evaluated in clinical trials.
In the US about 45,000 patients have been hospitalized with the disease, according to the Centers for Disease Control and Prevention*.
Ensifentrine’s novel pharmacology suggests it may be beneficial in COVID-19. We believe ensifentrine, with its novel mechanism of action, has the potential to improve oxygenation and lung function to assist recovery from COVID-19, which may differentiate it from other molecules in development for COVID-19. Verona Pharma plans to initiate a pilot clinical study in the third quarter of 2020 to evaluate ensifentrine delivered via pressurized metered-dose inhaler formulation as a treatment for patients hospitalized with COVID-19.
*As of August 19, 2020